Thrombotargets Corporation Receives Orphan Drug Designation from U S Food and Drug Administration for its Procoagulant Agent TT 103MH in the Treatment of Bleeding Episodes in Hemophiliacs Pages on BioPortfolio:

Thrombotargets Corporation Receives Orphan Drug Designation from ...
Thrombotargets Corporation Receives Orphan Drug Designation from the US Food and Drug Administration for its Procoagulant Agent, TT-103MH, in the Treatment ...
http://www.bioportfolio.com/biotech_news/Thrombotargets_1.ht...

BioPortfolio - ThromboTargets Corporation
Thrombotargets Corporation Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Procoagulant Agent, TT-103MH, ...
http://www.bioportfolio.com/biocorporate/31064-Thrombo_Targe...

Biotechnology and Pharmaceutical News Site Map
DuoCort Gets Orphan Drug Designation in the US for Treatment of Adrenal ...... the U.S. Food and Drug Administration for its Procoagulant Agent, TT-103MH, ...
http://www.bioportfolio.com/biotech_news/site_map.htm...

Results from other life science and pharmaceutical sites:

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.